Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
|Articles|September 21, 2021
OM Pharma Wins Geneva Economy Award
Advertisement
OM Pharma, a Geneva, Switzerland-based biopharmaceutical company, active in the prevention of recurrent respiratory and urinary tract infections and the treatment of vascular diseases has won the 2021 Geneva Economy Award.
The Geneva Economy and Innovation Awards, created in 2012, aim to honor companies whose reputation and influence convey a positive and dynamic image of Geneva.
The independent jury noted OM Pharma’s economic and social policy. Aiming at the long-term development of the company, all its profits are reinvested in research and development (R&D) and the expansion of its Geneva site.
OM Pharma is a private company founded in Geneva in 1937. The company employs a total of 400 people, including 300 in Geneva and 40 in Fribourg.
Advertisement
Related to this article
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5